Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908014725> ?p ?o ?g. }
- W2908014725 abstract "Restless legs syndrome (RLS) is a common neurologic disorder that is associated with peripheral iron deficiency in a subgroup of patients. It is unclear whether iron therapy is effective treatment for RLS.To evaluate the efficacy and safety of oral or parenteral iron for the treatment of restless legs syndrome (RLS) when compared with placebo or other therapies.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, PsycNFO, and CINAHL for the time period January 1995 to September 2017. We searched reference lists for additional published studies. We searched Clinicaltrials.gov and other clinical trial registries (September 2017) for ongoing or unpublished studies.Controlled trials comparing any formulation of iron with placebo, other medications, or no treatment, in adults diagnosed with RLS according to expert clinical interview or explicit diagnostic criteria.Two review authors independently extracted data and assessed trial quality, with discussion to reach consensus in the case of any disagreement. The primary outcome considered in this review was restlessness or unpleasant sensations, as experienced subjectively by the patient. We combined treatment/control differences in the outcomes across studies using random-effects meta-analyses. We analysed continuous data using mean differences (MDs) where possible and performed standardised mean difference (SMD) analyses when different measurements were used across studies. We calculated risk ratios (RRs) for dichotomous data using the Mantel-Haenszel method and 95% confidence intervals (CIs). We analysed study heterogeneity using the I2 statistic. We used standard methodological procedures expected by Cochrane. We performed GRADE analysis using GRADEpro.We identified and included 10 studies (428 total participants, followed for 2-16 weeks) in this review. Our primary outcome was restlessness or uncomfortable leg sensations, which was quantified using the International Restless Legs Scale (IRLS) (range, 0 to 40) in eight trials and a different RLS symptom scale in a ninth trial. Nine studies compared iron to placebo and one study compared iron to a dopamine agonist (pramipexole). The possibility for bias among the trials was variable. Three studies had a single element with high risk of bias, which was lack of blinding in two and incomplete outcome data in one. All studies had at least one feature resulting in unclear risk of bias.Combining data from the seven trials using the IRLS to compare iron and placebo, use of iron resulted in greater improvement in IRLS scores (MD -3.78, 95% CI -6.25 to -1.31; I2= 66%, 7 studies, 345 participants) measured 2 to 12 weeks after treatment. Including an eighth study, which measured restlessness using a different scale, use of iron remained beneficial compared to placebo (SMD -0.74, 95% CI -1.26 to -0.23; I2 = 80%, 8 studies, 370 participants). The GRADE assessment of certainty for this outcome was moderate.The single study comparing iron to a dopamine agonist (pramipexole) found a similar reduction in RLS severity in the two groups (MD -0.40, 95% CI -5.93 to 5.13, 30 participants).Assessment of secondary outcomes was limited by small numbers of trials assessing each outcome. Iron did not improve quality of life as a dichotomous measure (RR 2.01, 95% CI 0.54 to 7.45; I2=54%, 2 studies, 39 participants), but did improve quality of life measured on continuous scales (SMD 0.51, 95% CI 0.15 to 0.87; I2= 0%, 3 studies, 128 participants), compared to placebo. Subjective sleep quality was no different between iron and placebo groups (SMD 0.19, 95% CI -0.18 to 0.56; I2 = 9%, 3 studies, 128 participants), nor was objective sleep quality, as measured by change in sleep efficiency in a single study (-35.5 +/- 92.0 versus -41.4 +/- 98.2, 18 participants). Periodic limb movements of sleep were not significantly reduced with iron compared to placebo ( SMD -0.19, 95% CI -0.70 to 0.32; I2 = 0%, 2 studies, 60 participants). Iron did not improve sleepiness compared to placebo, as measured on the Epworth Sleepiness Scale (data not provided, 1 study, 60 participants) but did improve the daytime tiredness item of the RLS-6 compared to placebo (least squares mean difference -1.5, 95% CI -2.5 to -0.6; 1 study, 110 participants). The GRADE rating for secondary outcomes ranged from low to very low.Prespecified subgroup analyses showed more improvement with iron in those trials studying participants on dialysis. The use of low serum ferritin levels as an inclusion criteria and the use or oral versus intravenous iron did not show significant subgroup differences.Iron did not result in significantly more adverse events than placebo (RR 1.48, 95% CI 0.97 to 2.25; I2=45%, 6 studies, 298 participants). A single study reported that people treated with iron therapy experienced fewer adverse events than the active comparator pramipexole.Iron therapy probably improves restlessness and RLS severity in comparison to placebo. Iron therapy may not increase the risk of side effects in comparison to placebo. We are uncertain whether iron therapy improves quality of life in comparison to placebo. Iron therapy may make little or no difference to pramipexole in restlessness and RLS severity, as well as in the risk of adverse events. The effect on secondary outcomes such as quality of life, daytime functioning, and sleep quality, the optimal timing and formulation of administration, and patient characteristics predicting response require additional study." @default.
- W2908014725 created "2019-01-11" @default.
- W2908014725 creator A5022239109 @default.
- W2908014725 creator A5066463668 @default.
- W2908014725 date "2019-01-04" @default.
- W2908014725 modified "2023-10-14" @default.
- W2908014725 title "Iron for the treatment of restless legs syndrome" @default.
- W2908014725 cites W1848465532 @default.
- W2908014725 cites W1905286035 @default.
- W2908014725 cites W1905469088 @default.
- W2908014725 cites W1965076695 @default.
- W2908014725 cites W1965146150 @default.
- W2908014725 cites W197066864 @default.
- W2908014725 cites W1977809194 @default.
- W2908014725 cites W1981352341 @default.
- W2908014725 cites W1984954458 @default.
- W2908014725 cites W1985237673 @default.
- W2908014725 cites W1991348233 @default.
- W2908014725 cites W2019728909 @default.
- W2908014725 cites W2021031709 @default.
- W2908014725 cites W2026336009 @default.
- W2908014725 cites W2029320046 @default.
- W2908014725 cites W2037377025 @default.
- W2908014725 cites W2041306028 @default.
- W2908014725 cites W2041778817 @default.
- W2908014725 cites W2046551865 @default.
- W2908014725 cites W2056419871 @default.
- W2908014725 cites W2058590361 @default.
- W2908014725 cites W2059230191 @default.
- W2908014725 cites W2062745848 @default.
- W2908014725 cites W2064340631 @default.
- W2908014725 cites W2070187151 @default.
- W2908014725 cites W2079596123 @default.
- W2908014725 cites W2086951526 @default.
- W2908014725 cites W2089199151 @default.
- W2908014725 cites W2091605545 @default.
- W2908014725 cites W2094682665 @default.
- W2908014725 cites W2095407711 @default.
- W2908014725 cites W2098458127 @default.
- W2908014725 cites W2101810617 @default.
- W2908014725 cites W2109346853 @default.
- W2908014725 cites W2112139477 @default.
- W2908014725 cites W2114242035 @default.
- W2908014725 cites W2115937145 @default.
- W2908014725 cites W2116642832 @default.
- W2908014725 cites W2119092006 @default.
- W2908014725 cites W2122317547 @default.
- W2908014725 cites W2123128199 @default.
- W2908014725 cites W2129737373 @default.
- W2908014725 cites W2130564172 @default.
- W2908014725 cites W2139041137 @default.
- W2908014725 cites W2139927499 @default.
- W2908014725 cites W2141893227 @default.
- W2908014725 cites W2142359177 @default.
- W2908014725 cites W2147694941 @default.
- W2908014725 cites W2149311055 @default.
- W2908014725 cites W2151487996 @default.
- W2908014725 cites W2157103725 @default.
- W2908014725 cites W2168367269 @default.
- W2908014725 cites W2170092556 @default.
- W2908014725 cites W2170773352 @default.
- W2908014725 cites W2170892587 @default.
- W2908014725 cites W222867287 @default.
- W2908014725 cites W2259943788 @default.
- W2908014725 cites W2404415139 @default.
- W2908014725 cites W2408799309 @default.
- W2908014725 cites W2508442572 @default.
- W2908014725 cites W2553987300 @default.
- W2908014725 cites W2557184450 @default.
- W2908014725 cites W2594467170 @default.
- W2908014725 cites W2669264138 @default.
- W2908014725 cites W4237482061 @default.
- W2908014725 cites W4292806894 @default.
- W2908014725 doi "https://doi.org/10.1002/14651858.cd007834.pub3" @default.
- W2908014725 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6353229" @default.
- W2908014725 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30609006" @default.
- W2908014725 hasPublicationYear "2019" @default.
- W2908014725 type Work @default.
- W2908014725 sameAs 2908014725 @default.
- W2908014725 citedByCount "18" @default.
- W2908014725 countsByYear W29080147252019 @default.
- W2908014725 countsByYear W29080147252020 @default.
- W2908014725 countsByYear W29080147252021 @default.
- W2908014725 countsByYear W29080147252022 @default.
- W2908014725 countsByYear W29080147252023 @default.
- W2908014725 crossrefType "journal-article" @default.
- W2908014725 hasAuthorship W2908014725A5022239109 @default.
- W2908014725 hasAuthorship W2908014725A5066463668 @default.
- W2908014725 hasBestOaLocation W29080147252 @default.
- W2908014725 hasConcept C118552586 @default.
- W2908014725 hasConcept C119423318 @default.
- W2908014725 hasConcept C126322002 @default.
- W2908014725 hasConcept C142724271 @default.
- W2908014725 hasConcept C16568411 @default.
- W2908014725 hasConcept C168563851 @default.
- W2908014725 hasConcept C17744445 @default.
- W2908014725 hasConcept C1862650 @default.
- W2908014725 hasConcept C187212893 @default.
- W2908014725 hasConcept C187960798 @default.
- W2908014725 hasConcept C199539241 @default.